NOTE: The following includes references to in the online news media. If you are interested in seeing the full article you will need to contact archives department of the source publication. We do not have copies of any articles described on this site.

Alkermes (ALKS)

Alkermes

SkyePharma mystery as news of sale talks leaks out
[excerpt] Speculation centered on Nasdaq-listed Alkermes Inc, which specialises in sustained-release injection technologies. Alkermes has a market value of £670m. ... [/excerpt]
On Dec 1, 2004 in Guardian

GTC Biotherapeutics Announces the Elections of Kenneth A. Bauer ...
[excerpt] Board of Directors has elected Kenneth A. Bauer, MD of Beth Israel Deaconess Medical Center and Harvard Medical School, and Michael J. Landine of Alkermes, Inc ... [/excerpt]
On Dec 9, 2004 in Business Wire (press release)

Zyprexa Issues Are Key Drivers For Eli Lilly
[excerpt] ...our 'equal-weight' rating on the stock." Lilly remains committed to the inhaled insulin program they are pursuing in collaboration with Alkermes (nasdaq: ALKS ... [/excerpt]
On Dec 10, 2004 in Forbes

Sirtris Pharmaceuticals, the Leading Class III Histone Deacetylase ...
[excerpt] ...advisory board includes several members with experience founding and building leading biotechs such as Genetics Institute, Biogen, Alkermes, Momenta, Alnylam ... [/excerpt]
On Dec 1, 2004 in mysan.de,